Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
Skip to main content

The devastating 2013-2015 outbreak of Ebola Virus disease in West Africa provided the impetus for acceleration of multiple programmes of Ebola Vaccine development.

Ebola 2 © Shutterstock

One of the Ebola vaccine development programmes employed a schedule in which two different vaccines were given in a ‘prime/boost’ schedule. Both of these vaccines used a ‘viral vector’ technology, in which genes encoding for key Ebola virus proteins were inserted into non-replicating, non-pathogenic viruses: adenovirus 26 (Ad26) and modified vaccinia Anakara MVA).

Two studies of these vaccines (Ad26.ZEBOV and MVA-BN-Filo) have been conducted at the Oxford Vaccine Group, both designed to obtain information about the safety and immune response in healthy adults.

Completed Clinical Research

The first-in-human, ‘Phase 1’, study was conducted from December 2014 to May 2016, and enrolled 87 participants. The results from this study showed that immunisation with Ad26.Zeboc is able to stimulate an immune response that is then boosted by administration of MVA-BN-Filo. No significant safety concerns were raised.

A larger, phase 2, study is currently underway to characterise the immune response to these vaccines in more detail.

Ongoing Clinical Research

This vaccine schedule is now being evaluated in clinical trials being conducted in West Africa, to ensure that the immune response seen in a UK population is also observed in areas more at risk for Ebola Virus outbreaks.

Our team